News

Public · Published

MYGN: Q3 progress and higher guidance accompany a $210M Prenatal Health divestiture

Myriad Genetics reported quarterly revenue of $202.7 million, improved profitability compared with the prior quarter, and a higher midpoint for its full-year revenue guidance. It also plans to sell its Prenatal Health business to Labcorp for $210 million plus inventory, intending to sharpen its focus on cancer testing.

Published:

Updated:

What happened

Myriad Genetics reported quarterly revenue of $202.7 million, improved profitability compared with the prior quarter, and a higher midpoint for its full-year revenue guidance. It also plans to sell its Prenatal Health business to Labcorp for $210 million plus inventory, intending to sharpen its focus on cancer testing.

Confirmed

Global impact / market context

The planned sale would transfer Prenatal Health operations to Labcorp and bring Myriad cash plus the value of inventory, while reducing the business areas it manages. If completed, sharper focus on cancer testing could redirect company resources, but the article gives no expected proceeds after costs or operating impact.

Analyst inference

The update combines stronger reported quarterly revenue and profitability with a planned business sale, rather than announcing a completed transaction. The raised guidance midpoint signals improved expectations for full-year revenue, while the sale’s value to investors depends on closing and how Myriad uses the proceeds.

Analyst inference

What to watch

  1. Watch for confirmation that the Labcorp sale closes, since the article describes it as planned; completion would determine when Myriad transfers the business and receives payment. Analyst inference
  2. Look for details on the final sale terms, including how inventory is treated, because the stated $210 million is in addition to inventory. Confirmed
  3. Compare subsequent revenue guidance and profitability with this quarter’s results to see whether Myriad’s stronger performance continues as it focuses on cancer testing. Analyst inference

Evidence

  • Original source link unavailable